Postmenopausal hormone therapy and breast cancer

Obstetrics and Gynecology

Volumn 87, Issue 2 II SUPPL., 1996, Pages

  Speroff, Leon ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; BELLERGAL; BROMOCRIPTINE; CLONIDINE; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; METHYLDOPA; NALOXONE; NORGESTREL; ORAL CONTRACEPTIVE AGENT; TAMOXIFEN; VERALIPRIDE;

BREAST CANCER; BREAST DISEASE; CANCER INCIDENCE; CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DOSE RESPONSE; ESTROGEN THERAPY; FAMILY HISTORY; FEMALE; GALACTORRHEA; HOT FLUSH; HUMAN; INTRAVAGINAL DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MAMMOGRAPHY; MASTALGIA; META ANALYSIS; OBESITY; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK BENEFIT ANALYSIS; TRANSDERMAL DRUG ADMINISTRATION; VAGINA ATROPHY;

EID: 0030052566     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/0029-7844(95)00428-9     Document Type: Article

References (81)

1. Cancer facts & figures. American Lancer Society, 1994.
2. Bergkvist L, Adami H-O, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989;321:293-7.
3. Bergkvist L, Adami H-O, Persson I, Bergstrom R, Krusemo UB. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am J Epidemiol 1989;130:221-7.
4. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988;42:832-8.
5. Brinton LA, Hoover R, Fraumeni JF Jr. Menopausal oestrogens and breast cancer risk: An expanded case-control study. Br J Cancer 1986;54:825-32.
6. Hiatt RA, Bawol R, Friedman GD, Hoover R. Exogenous estrogen and breast cancer after bilateral oophorectomy. Cancer 1984;54: 139-44.
7. Hoover R, Gray LA Sr, Cole P, MacMahon B. Menopausal estrogens and breast cancer. N Engl J Med 1976;295:401-5.
8. Hoover R, Glass A, Finkle WE, Azevedo D, Milne K. Conjugated estrogens and breast cancer risk in women. J Natl Cancer Inst 1981;67:815-20.
9. Hulka BS, Chambless LE, Deubner DC, Wilkinson WE. Breast cancer and estrogen replacement therapy. Am J Obstet Gynecol 1982;143:638-44.
10. Jick H, Walker AM, Watkins R, et al. Replacement estrogens and breast cancer. Am J Epidemiol 1980;112:586-94.
11. Kaufman DW, Miller DR, Rosenberg L, et al. Noncontraceptive estrogen use and the risk of breast cancer. JAMA 1984;252:63-7.
12. Kelsey JL, Fischer DB, Holford TR, et al. Exogenous estrogens and other factors in the epidemiology of breast cancer. J Natl Cancer Inst 1981;67:327-33.
13. Lawson DH, Jick H, Hunter JR, Madsen S. Exogenous estrogens and breast cancer. Am J Epidemiol 1981;114:710-3.
14. Ross RK, Paganini-Hill A, Gerkins VR, et al. A case-control study of menopausal estrogen therapy and breast cancer. JAMA 1980; 243:1635-9.
15. Wingo PA, Layde PM, Lee NC, Rubin G, Ory HW. The risk of breast cancer in postmenopausal women who have used estrogen replacement therapy. JAMA 1987;257:209-15
16. Colditz GA, Stampfer MJ, Willett WC, et al. Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses' Health Study. Cancer Causes Control 1992;3: 433-9.
17. Colditz GA, Hankinson SE, Hunter DJ, et al. Use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589-93.
18. Vrieze OJ, Kuipers J, Boes G. Scenario analysis in public health and competing risks. Stat Applicats 1990;1:371-7.
19. Rohan TE, McMichael AJ. Non-contraceptive exogenous oestrogen therapy and breast cancer. Med J Aust 1988;148:217-21.
20. Dupont WD, Page DL, Rogers LW, Pari FF. Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk. Cancer 1989;63:948-57.
21. Kaufman DW, Palmer JR, De Mouzon J, et al. Estrogen replacement therapy and the risk of breast cancer: Results from the case-control surveillance study. Am J Epidemiol 1991;134:1375-85.
22. Palmer JR, Rosenberg L, Clarke EA, Miller DR, Shapiro S. Breast cancer risk after estrogen replacement therapy: Results from the Toronto Breast Cancer Study. Am J Epidemiol 1991;134:1386-95.
23. Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137-42.
24. Yang CP, Daling JR, Band PR, Gallagher RP, White E, Weiss NS. Noncontraceptive hormone use and risk of breast cancer. Cancer Causes Control 1992;3:475-9.
25. Risch HA, Howe GR. Menopausal hormone usage and breast cancer in Saskatchewan: A record-linkage cohort study. Am J Epidemiol 1994;139:670-83.
26. Schairer C, Byrne C, Keyl PM, Brinton LA, Sturgeon SR, Hoover RN. Menopausal estrogen and estrogen-progestin replacement therapy and risk of breast cancer (United States). Cancer Causes Control 1994;5:491-500.
27. Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis: Methods for quantitative synthesis in medicine. New York: Oxford University Press, 1994.
28. Armstrong BK. Oestrogen therapy after the menopause - boon or bane? Med J Aust 1988;148:213-4.
29. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151:67-72.
30. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985-90.
31. Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R. Menopausal hormone replacement therapy and breast cancer: A meta-analysis. Obstet Gynecol 1992;79:286-94.
32. Colditz GA, Egan KM, Stampfer MJ. Hormone replacement therapy and risk of breast cancer: Results from epidemiologic studies. Am J Obstet Gynecol 1993;168:1473-80.
33. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
34. Strickland DM, Gambrell RD Jr, Butzin CA, Strickland K. The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynecol 1992;80:400-4.
35. Hunt K, Vessey M, McPherson K. Mortality in a cohort of long-term users of hormone replacement therapy: An updated analysis. Br J Obstet Gynaecol 1990;97:1080-6.
36. Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 1995;85:11-7.
37. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151: 75-8.
38. Gambrell RD Jr, Maier RC, Sanders BI. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 1983;62:435-43.
39. Nachtigall MJ, Smilen SW, Nachtigall RAD, Nachtigall RH, Nachtigall LI. Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol 1992;80:827-30.
40. Korenman SG. The endocrinology of breast cancer. Cancer 1980; 46:874-8.
41. Korenman SG. Estrogen window hypothesis of the etiology of breast cancer. Lancet 1980;700-1.
42. Coulam CB, Annegers JF, Kranz JS. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 1983;61:403-7.
43. Cowan LD, Gordis L, Tonascia JA, Jones GS. Breast cancer incidence in women with a history of progesterone deficiency. Am J Epidemiol 1981;114:209-17.
44. Ron E, Lunenfeld B, Menczer J, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1987;125:780-90.
45. Gammon MD, Thompson WD. Infertility and breast cancer: A population-based case-control study. Am J Epidemiol 1990;132: 708-16.
46. Gammon MD, Thompson WD. Polycystic ovaries and the risk of breast cancer. Am J Epidemiol 1991;134:818-24.
47. Key TJA, Pike MC. The role of oestrogens and progestogens in the epidemiology and prevention of breast cancer. Eur J Cancer Clin Oncol 1988;24:29-43.
48. Henderson BE, Ross RK, Judd HL, Krailo MD, Pike MC. Do regular ovulatory cycles increase breast cancer risk? Cancer 1985; 56:1206-8.
49. Anderson TJ, Ferguson DJP, Raab GM. Cell turnover in the "resting" human breast: Influence of parity, contraceptive pill, age and laterality. Br J Cancer 1982;46:376-82.
50. Gompel A, Malet C, Spritzer P, Lalardrie J-P, Kuttenn F, Mauvais-Jarvis P. Progestin effect on cell proliferation and 17b-hydroxysteroid dehydrogenase activity in normal human breast cells in culture. J Clin Endocrinol Metab 1986;63:1174-80.
51. Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocrinol Rev 1990;11:266-301.
52. Zemlickis D, Lishner M, Degendorter P, et al. Maternal and fetal outcome after breast cancer in pregnancy. Am J Obstet Gynecol 1992;166:781-7.
53. Saunders CM, Baum M. Breast cancer and pregnancy: A review. J R Soc Med 1993;86:162-5.
54. Lambe M, Hsieh C, Trichopoulos D, Ekbom A, Pavia M, Adami HO. Transient increase in the risk of breast cancer after giving birth. N Engl J Med 1994;331:5-9.
55. Guinee VF, Olsson H, Moller T, et al. Effect of pregnancy on prognosis for young women with breast cancer. Lancet 1994;343: 1587-9.
56. Ribeiro G, Jones DA, Jones M. Carcinoma of the breast associated with pregnancy. Br J Surg 1986;73:607-9.
57. Sankila R, Heinavaara S, Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy: "Healthy mother effect." Am J Obstet Gynecol 1994;170:818-23.
58. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Breast cancer and depot-medroxyprogesterone acetate: A multinational study. Lancet 1991;338:833-8.
59. Lee NC, Rosero-Bixby L, Oberle MW, Grimaldo C, Whatley AS, Rovira EZ. A case-control study of breast cancer and hormonal contraception in Costa Rica. J Natl Cancer Inst 1987;79:1247-54.
60. Paul C, Skegg DCG, Spears GFS. Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer. Br Med J 1989;299:759-62.
61. Skegg DCG, Noonan EA, Paul C, Spears GFS, Meirik O, Thomas DB. Depot medroxyprogesterone acetate and breast cancer: A pooled analysis of the World Health Organization and New Zealand studies. JAMA 1995;273:799-804.
62. Spicer D, Pike MC, Henderson BE. The question of estrogen replacement therapy in patients with a prior diagnosis of breast cancer. Oncology 1990;4:49-54.
63. Stoll BA, Parbhoo S. Treatment of menopausal symptoms in breast cancer patients. Lancet 1988;i:1278-9.
64. Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients. Am J Surg 1993;165:372-5.
65. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. N Engl J Med 1992; 326:1756-61.
66. Henderson IC. Breast cancer therapy - the price of success. N Engl J Med 1992;326:1774-5.
67. Love RR, Mazess RB, Tormey DC, Barden HS, Newcomb PA, Jordan VC. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 1988;12:297-302.
68. Fornander T, Rutquist LE, Sjoberg HE, Blomqvist L, Mattsson A, Glas U. Long-term adjuvant tamoxifen in early breast cancer: Effect on bone mineral density in postmenopausal women. J Clin Oncol 1990;8:1019-24.
69. Turken S, Siris E, Seldin D, Flaster E, Hyman G, Lindsay R. Effects of tamoxifen on spinal bone density in women with breast cancer. J Natl Cancer Inst 1989;81:1086-8.
70. Love RR, Mazess RB, Barden HS, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852-6.
71. Ryan WG, Wolter J, Bagdade JD. Apparent beneficial effects of tamoxifen on bone mineral content in patients with breast cancer: Preliminary study. Osteoporosis Int 1991;2:29-41.
72. Bertelli G, Pronzato P, Amoroso D, et al. Adjuvant tamoxifen in primary breast cancer: Influence on plasma lipids and antithrombin III levels. Breast Cancer Res Treat 1988;12:307-10.
73. Bagdade JD, Wolter J, Subbaiah PV, Ryan W. Effects of tamoxifen treatment on plasma lipids and lipoprotein composition. J Clin Endocrinol Metab 1990;70:1132-5.
74. Dewar JA, Horobin JM, Preece PE, Tavendale R, Tunstall-Pedoe H, Wood RAB. Longterm effects of tamoxifen on blood lipid values in breast cancer. Br Med J 1992;305:225-6.
75. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst 1994;86:534-9.
76. McDonald CC, Stewart HG. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. Br Med J 1991;303:435-7.
77. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. J Natl Cancer Inst 1993; 85:1398-406.
78. Love RR, Cameron L, Connell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med 1991;151:1842-7.
79. Goldberg RM, Loprinzi CL, O'Fallen JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994;12:155.
80. Rigg LA, Hermann H, Yen SSC Absorption of estrogens from vaginal creams. N Engl J Med 1978;298:195-8.
81. Nilsson K, Heimer G. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency - a pharmacokinetic and pharmacodynamic study. Maturitas 1992;15:121-7.